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A Golden Age for Working
with Public Proteomics Data
Lennart Martens1,2,3,*,@ and Juan Antonio Vizcaíno4,*,@
[382_TD$DIFF] ata sharing in mass spectrometry (MS)-based proteomics is becoming a
common scientiﬁc practice, as is now common in the case of other, more
mature ‘omics’ disciplines like genomics and transcriptomics. We want to
highlight that this situation, unprecedented in the ﬁeld, opens a plethora of
opportunities for data scientists. First, we explain in some detail some of the
work already achieved, such as systematic reanalysis efforts. We also explain
existing applications of public proteomics data, such as proteogenomics and
the creation of spectral libraries and spectral archives. Finally, we discuss the
main existing challenges and mention the ﬁrst attempts to combine public
proteomics data with other types of omics data sets.
MS-Based Proteomics Data in the Public Domain
MS-based proteomics approaches have evolved rapidly over recent years. These approaches
are therefore increasingly used to disentangle intricate biological questions, often together with
other omics disciplines (e.g., genomics, transcriptomics, metabolomics) [1–3]. A key signal of
thematurity of the ﬁeld is the common acceptance of public data sharing (as embraced earlier in
genomics and transcriptomics) as good scientiﬁc practice. This important change of mentality
has been triggered by requirements from scientiﬁc journals and funding agencies on the one
hand [4] and by the availability of reliable and more user-friendly resources and tools to support
data sharing on the other hand [5,6].
The ﬁrst MS proteomics resources were set up more than 10 years ago, notably PeptideAtlas
[7], GPMDB [8], and PRIDE (now renamed PRIDE Archive) [9,10], and these continue to be
leading resources worldwide. Through the years, other proteomics resources have appeared
and, regrettably, also disappeared [11]. However, at present the ﬁeld is experiencing a ‘golden
age’ for MS proteomics resources. Several notable resources have come into being, including
MassIVE (http://massive.ucsd.edu/), jPOST (http://jpost.org/), the Human Proteome Map
(http://www.humanproteomemap.org/), ProteomicsDB (https://www.proteomicsdb.org/),
and Chorus (https://chorusproject.org/) (for a recent review, see [12]). In 2011 some of the
most prominent resources in the ﬁeld came together and started to collaborate formally,
resulting in uniﬁed submission and data dissemination practices within the ProteomeXchange
(PX) Consortium [13] (http://www.proteomexchange.org/). At present, the PX members are
PRIDE, PeptideAtlas (including the PASSEL resource for targeted proteomics data [14]),
MassIVE, and jPOST.
Most of the data sets publicly available correspond to human and the main model organisms.
However, non-model organisms are also increasingly well represented. Data sets from more
than 900 different taxonomic identiﬁers are available in the various PX repositories [15]. The
data submission process has been described in detail elsewhere [12,16].
Because of these developments, we believe that the ﬁeld is now ﬁlled with opportunities
for those wanting to extract new knowledge from this abundance of data. While new in
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proteomics, such orthogonal reprocessing of public data is already common in even more
mature ﬁelds [17]. With a few notable exceptions (e.g., [7,8,18–20]), the data so far remain
largely untouched.
In this Opinion article, we discuss some of the challenges and possible future directions for
proteomics data resources and convince researchers of the utility of making their data publicly
available. Finally, we demonstrate the high number of exciting possibilities available for sci-
entists willing to work with these data.
Overview of the Ways in which Proteomics Data Can Be Reused
In proteomics the number of data types and their corresponding data formats can be
overwhelming. The main data types that need to be stored by proteomics repositories are
raw (MS data generated by the mass spectrometer) and analyzed (for identiﬁcation and
quantiﬁcation-based analyses). For PX data sets, it is mandatory to provide both data types,
since they provide complementary information and enable different types of data reuse. The
availability of raw data enables a full reanalysis of the data sets while the analyzed data can be
used, among other things, for visualizing and assessing the results reported in a given study.
The development of data standards has contributed to simplifying the use of public proteomics
data for scientists (Box 1). In a recent review [21], together with other colleagues we established
four categories of public proteomics data use: (i) use; (ii) reuse; (iii) reprocess; and (iv) repurpose.
An overview of the main applications is provided in Figure 1 (Key Figure).
A simple example of the direct use of data is given by connecting information between the
above-cited proteomics data resources and protein knowledge bases, such as UniProt [22]
and neXtProt [23]. This type of use is quite impactful because such knowledge bases are the
most likely conduit throughwhich researchers in the broader life sciences will beneﬁt from these
data.
In the case of reuse, public data are not only connected with complementary knowledge but
also reused in novel experiments with the potential to generate new knowledge. The creation
and use of spectral libraries and spectral archives represent a clear example (Box 2). In addition,
one generic type of data reuse, also popular in other disciplines, is the analysis of data from a
large number of independent data sets in combination, a so-called meta-analysis study, to
extract new knowledge not accessible from any one individual data set. Although there are
some notable examples of this type of study in the ﬁeld (e.g., [24,25]), such reuse remains
Box 1. Data Standards in Proteomics
The availability of data standards is crucial to public data sharing and such standards are therefore instrumental in the
advancement of any research ﬁeld. For the ﬁeld of MS-based proteomics, the PSI of the HUPO has taken the leading
role in developing the required controlled vocabularies, standard ﬁle formats, and minimal reporting requirements for
various aspects of MS proteomics data (for a recent review, see [55]). The most popular formats are: (i) mzML, which
stores raw MS data as well as processed peak list spectra [56]; (ii) mzIdentML, which captures the peptide and protein
identiﬁcations derived from MS data [57]; and (iii) mzQuantML, which captures detailed quantitative information [58].
Besides these three XML-based formats, a simpler, tab-delimited format called mzTab has been released that stores
both identiﬁcation and quantiﬁcation information [59].
Whereas mzML is already well adopted andmzIdentML is on track to become a successful format, the adoption of data
standards for quantitative data has not yet taken off. This is mainly due to the lack of support for these more recent
standards by most popular tools. A recent effort to create a standard to express QC metrics, named qcML, has also
been proposed [60]. Because standardization is so crucial to efﬁcient and accurate data sharing, it is vital that all of these
relevant standards becomewidely adopted as soon as possible. This will in turn enable proteomics data to become fully
accessible and reusable and will foster innovative approaches to make the most of these data. Disciplines such as
genomics and transcriptomics provide excellent examples for the type of rapid development that can occur when
standards adoption becomes ubiquitous.
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relatively scarce [21]. This comparative lack of published studies belies the many opportunities
that are available through such endeavors, however.
In the case of reprocess, public data are reanalyzed to provide an updated view on the results
as protein sequence databases (used by the majority of search engines in proteomics) evolve
and become more accurate. Such analyses, which are also common in other disciplines, have
goals the same as or similar to the original experiment, although the reprocess can deliver novel
ﬁndings. Resources such as PeptideAtlas and GPMDB routinely reprocess many datasets
using their dedicated bioinformatics tools and pipelines. The results from PeptideAtlas are
organized into builds, each including data from a single species proteome (e.g., human, pig,
Candida albicans) or subproteome (e.g., human plasma). Each build is generated by reanalyz-
ing the raw MS/MS spectra compiled by PeptideAtlas over the years or from data from other
public repositories, especially PRIDE[383_TD$DIFF]. Analogously, GPMDB reprocesses MS/MS data pro-
vided by users or raw data stored in other repositories. Both PeptideAtlas and GPMDB are
actively contributing to the Human Proteome Project (HPP) and are providing guidelines and a
consensus up-to-date list (updated each year) of the human proteins that have been detected
by MS [26]. In the context of the HPP, both resources are working closely together with
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neXtProt in the process providing a nice example of a reprocess effort by proteomics data
resources that leads to use of the obtained results by a knowledge base.
Finally, repurposing includes all those cases where the data are considered anew in a
context that differs from the original experiment. Two attractive applications of this type
of study are proteogenomics approaches and the discovery of novel post-translational
modiﬁcations (PTMs). Of course, before repurposing any data set it is important to obtain an
idea about its suitability to the purpose at hand. This is typically accomplished through
appropriate types of quality control (QC). In the following sections, we therefore ﬁrst discuss
QC of (public) proteomics data and then move on to the proteogenomics and PTM use
cases.
QC of Proteomics Data
In any analytical discipline, QC is very important [27]. However, QC has historically not been
as well developed in proteomics as in, for instance, small-molecules MS. Here, too, public
data availability can play a role as it enables a posteriori QC of the data [28]. Ideally, all data in
repositories should be linked to objective quality metrics, but this process has barely started
[5,29] as appropriate software tools have only recently become available [30,31]. At present,
proteomics resources are assessing the internal consistency of the data submitted (e.g.,
correspondence between the mass spectra and identiﬁcation results), detecting clear anno-
tation errors (e.g., related to PTMs), and ensuring an acceptable level of technical and
biological metadata. In addition, as a key point, the availability of free-to-use tools such
as PRIDE Inspector [5,32] enables potential errors to be detected by anyone in the
community.
Of course, QC metric calculation at the level of proteomics resources can serve only as a
postmortem, as potential issues can no longer be solved at that point. A perfect situation would
therefore see QC metrics produced in parallel with data acquisition in the laboratory and
subsequently communicated to repositories alongside the data.
Box 2. Spectral Libraries and Spectral Archives
In addition to the widely used sequence database-based approaches, several alternative analysis techniques exist that
can potentially improve the rate of identiﬁed spectra. One of the most popular approaches is the use of spectral library
searches, which rely on collections of previously identiﬁed experimental spectra (or consensus versions of those) called
spectral libraries. The creation of such libraries beneﬁts enormously from the accumulation of data in the public domain,
which allows the libraries to expand in terms of different species, mass spectrometers, and experimental approaches.
PeptideAtlas, GPMDB, PRIDE[379_TD$DIFF], and other organizations such as the National Institute of Standards and Technology
(NIST) all provide such spectral libraries. A recent use of spectral libraries is in the analysis of Data Independent
Acquisition (DIA) data, such as SWATH-MS [61]. For this particular use case, spectral libraries are typically generated by
individual laboratories using their own data. However, a new tool has been recently developed that can make use of
spectral libraries generated elsewhere, even in other types of mass spectrometers [62]. However, it should be noted that
reliable and consistent retention times are essential for this approach.
The main issues for spectral libraries are the accumulation of false-positive identiﬁcations that may be present in the
original spectral libraries and the difﬁculty of ﬁnding novel peptides not previously observed. This last limitation hinders
spectral library-based analysis approaches in SWATH-MS where, as mentioned, individual groups need to generate
comprehensive spectral libraries that need to cover all of the different samples and scenarios considered in the study.
This can represent a major effort that should not be underestimated.
Spectral archives are an extension of spectral libraries comprising collections of mass spectra that can include
unidentiﬁed spectra rather than only previously identiﬁed spectra. PRIDE has recently provided the ﬁrst spectral archive
version of a proteomics repository [63]. This archive was created using a spectrum-clustering approach that enabled the
detection of millions of consistently observed but unidentiﬁed spectra across hundreds of public data sets. By using
alternative analysis approaches, the authors managed to identify around 20% of these spectra, which illustrates that
more efforts are still needed to identify the remaining ones. It is not unreasonable to assume that a proportion of these
unidentiﬁed spectra correspond to unknown peptide sequence variants or unexpected PTMs.
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Proteogenomics
In proteogenomics proteomics data is combined with genomics and/or transcriptomics infor-
mation, typically using sequence databases generated from DNA sequencing efforts, RNA-seq
experiments, or Ribo-seq approaches, among others. The promise of these approaches is
that, if peptides are detected that cover events such as novel splice junctions, long noncoding
RNAs (lncRNAs), small open reading frames (ORFs), or pseudogenes, genome annotation can
be improved [33].
Proteogenomics approaches beneﬁt greatly from the availability of public data sets because it is
likely that the number of novel events detected in a single data set will be very small compared
with the data acquisition effort. Especially in the case of well-studied organisms (e.g., human), a
large number of public data sets are, however, already available. Several studies have been
published where public data have been used in proteogenomics projects for human (e.g.,
[19,34]), mouse [35], and rat [36][384_TD$DIFF], among other organisms. In addition, the complete compen-
dium of public data for humans has been reanalyzed to provide evidence-of-existence anno-
tation for the human lncRNAs stored in LNCipedia [37]. The latest trend is to use public data
together with Ribo-seq data for the determination of small ORFs [38].
In our opinion one of the key issues in proteogenomics at present is the lack of connection
between the researchers who performed the analyses and the resources that can update
genome annotation based on these new ﬁndings. Thankfully, this situation is improving, as
common genomics data formats are currently being extended by the Human Proteome
Organization (HUPO) Proteomics Standards Initiative (PSI) to also support proteomics infor-
mation [e.g., the proBed (http://www.psidev.info/probed) and proBAM (http://www.psidev.
info/probam) data formats]. These standard formats can already be used to generate ‘Track
Hubs’ [39], which can be provided by any interested third parties and which can be automati-
cally integrated into genome browsers such as Ensembl and the UCSC Genome Browser.
While this mechanism is not yet fully mature, the coming months are likely to see substantial
improvements.
The other big issue in proteogenomics studies is the accumulation of false positives, as
exempliﬁed in the human proteome draft papers mentioned in Box 3. Much more restrictive
quality criteria should be established for peptides describing novel genomics events [33].
Box 3. Human Proteome Drafts and Discussions
One of the beneﬁts of public data availability is that it enables independent assessment of the results described in
scientiﬁc publications. In the proteomics ﬁeld, too, there have been several examples of widely debated, controversial
ﬁndings [21]. These healthy discussions were triggered and enabled naturally by the public availability of the corre-
sponding data sets. The most prominent example occurred recently, surrounding the two human proteome drafts
published by the Pandey [64] and Kuster [18] groups. To their considerable credit, both teams made their correspond-
ing raw MS data publicly available and, moreover, created online resources to facilitate access to their results: the
Human Proteome Map and ProteomicsDB, respectively. Based on thus-enabled detailed scrutiny, the ﬁndings in these
two papers have been criticized bymany,mainly due to a lack of stringency in data analysis (e.g., in [65]). This causes the
accumulation of false-positive identiﬁcations due to associated underestimation of the false-discovery rate (FDR).
Meanwhile, several groups have been extracting novel conclusions from reanalysis of these data [19], and it is expected
that these extensive data sets will continue to generate novel ﬁndings for some time. As an important aside, it is
particularly interesting to note that the human proteome draft generated by the Kuster group already relies on reanalyses
of other researchers’ data sets from public resources for around 60% of its contents.
Additionally, data reliability in the ﬁeld can also be improved indirectly by facilitating the development and benchmarking
of improved software analysis tools, which will potentially increase the data reliability of future studies. In this context of
software development, there are multiple examples of reuse of public data sets [21]. The existence of benchmarking
data sets is essential and efforts have been made to speciﬁcally promote their public availability [66].
Trends in Biochemical Sciences, May 2017, Vol. 42, No. 5 337
Moreover, the enlarged sequence search space of typical proteogenomics searches can lead
to undesirable ambiguity of identiﬁcation [40].
PTM-Related Studies
Proteomics approaches (both MS and antibody based) provide the sole means of detecting
and localizing protein PTMs. Of the many known PTMs, phosphorylation is by far the most
studied, and as a result the number of phosphoproteomics data sets in the public domain is
large and growing. Several highly valuable resources, such as PhosphoSitePlus [41], are
specialized in compiling phosphorylation-related information from various sources, including
MS proteomics resources, constituting another elegant example of a simple use of the data.
However, public datasets are also being reanalyzed to extract new knowledge in the context of
PTM-related research. For instance, the spread of detected phosphosites on protein structure
has been analyzed, and in a recent study three large phosphoproteomics data sets (including
two public ones) were reanalyzed as a starting point for the generation of robust targeted MS
assays [20]. The resulting assay data are available in a novel resource called Phosphopedia.
The same approach could be applied to other PTMs as the number of relevant public data sets
grows. Finally, as mentioned above, it is also possible to repurpose the analysis of existing data
sets to look for PTMs that were not initially considered in the searches. To our knowledge the
only successful studies so far have used enriched phosphoproteomics data sets to ﬁnd
serendipitously co-enriched peptides bearing unusual modiﬁcations [42,43].
Glycosylation represents a widely occurring PTM. It would be highly beneﬁcial to achieve a
closer interaction between existing proteomics and glycomics resources [44]. At present, to the
best of our knowledge, these efforts have barely started.
Integration of Proteomics Data Sets with Other Public Omics Data Sets
It becomes steadily easier as well as more rewarding to combine public proteomics data with
other public omics data, which opens a multitude of novel opportunities for data scientists.
Proteogenomics approaches have recently, for instance, been used to study various cancers,
focusing on cancer-speciﬁc peptides for diagnostic and therapeutic purposes. The Clinical
Proteomic Tumor Analysis Consortium (CPTAC) of the National Cancer Institute (NCI) has
released several high-proﬁle studies for several tumor types, including colorectal [45], breast
[46], and ovarian [47]. These data are all publicly available at least through the CPTAC Data
Portal and represent a typical example where the protein sequence databases used for the
analysis are directly derived from the corresponding exome sequences from the cancer
samples.
However, at present, in most cases it is not trivial for researchers to connect data [37_TD$DIFF]sets that have
been generated in multiomics studies. Two exceptions are consortia that have their own data
repository or portal (like CPTAC) and organism-speciﬁc resources such as the ‘Saccharomyces
Genome database’. This is because the ﬁrst substantial obstacle for integrative data scientists
is ﬁnding suitable data sets to link. This key issue is being addressed by the Omics Discovery
Index (OmicsDI) (http://www.omicsdi.org/), a recently released portal for the discovery and
access of data sets from various omics approaches and online resources [48]. Among other
features, OmicsDI represents the concept of multiomics data sets by connecting different
omics datasets cited in the same publication. For instance, in September 2016 OmicsDI knew
about more than 30 multiomics data sets that contain both proteomics data and the corre-
sponding gene expression data. Indeed, the ﬁrst examples of studies combining public
proteomics and gene expression data sets already exist [49]. This type of multiomics study
involving proteomics data will only grow as public data deposition generalizes for all omics
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disciplines and the data sets are better connected. Publications combining proteomics and
lipidomics/metabolomics approaches are starting to appear [50].
Challenges
The lack of experimental and technical metadata has been highlighted many times as the main
issue for the reuse of biological data, and particularly in proteomics [51]. The metadata
requirements of proteomics resources in general are much less comprehensive than those
of equivalent resources frommoremature omics ﬁelds, leading tomore pronounced annotation
problems for proteomics data. In our experience there needs to be a balance between the
required amount of metadata and the willingness of researchers to share their data. Scientists
try to avoid ‘administrative’ work as much as possible. Because the data-sharing culture
started more recently in proteomics than in other disciplines, the main focus so far has been
facilitating the process of data sharing as much as possible, from both a technical and a time-
efﬁciency point of view. Raising the bar in terms ofmetadata requirements is an achievable goal,
as far as proteomics resources have the means to evolve their systems and tools. Unfortu-
nately, the latter can be challenging in the current funding situation as it is often perceived that all
issues in this area have been solved. In this context, as a ‘silver lining’, it is important to highlight
that the increased adoption of the data standards is key to improving the situation, as much
metadata (especially the proteomics-speciﬁc metadata) can be extracted automatically from
the acquired data ﬁles instead of having to be entered manually by the submitters.
In the near future, one challenge that may arise is the existence of limited access to human
clinical proteomics data, as is common today for genomics and transcriptomics data sets,
where specialized, access-controlled resources such as the European Genotype Archive (EGA)
(https://www.ebi.ac.uk/ega/) and dbGaP (http://www.ncbi.nlm.nih.gov/gap/) have to be used.
Access to these data is granted only after applications are reviewed by an ethics committee.
The ﬁrst studies describing the possibility of recognizing speciﬁc patients using proteomics data
have just been published [52,53]. Whether access limitations will ultimately apply to clinical
proteomics data remains to be seen, but undoubtedly this topic will become an important
matter for discussion in the near future.
Concluding Remarks and Future Perspectives
We hope to have convinced the reader that there is a bright future for data scientists in the MS
proteomics ﬁeld (see Outstanding Questions). Regrettably, the term ‘research parasites’ has
recently been bandied about to describe those who work with publicly available data generated
by others [54]. In our opinion this term is not justiﬁed for two reasons. First, the scientists who
generated the data originally should, of course, be acknowledged and given proper recognition
and citation, and in our experience this has been, and remains, the default scientiﬁc behavior.
Nevertheless, there will always be researchers who fail to cite their sources adequately and this
is certainly not unique to the reuse of public data. However, public data sharing should not be
stalled because of a small minority of researchers that are not complying with these basic
practices. Second, if data has not yet been analyzed in full by the originator at the time of
publication, it can hardly be termed parasitism if others attempt to further optimize the value of
these data by analyzing them, especially if they do so in innovative and orthogonal ways.
Instead, one would expect that any mature ﬁeld of research should welcome novel insights that
can be derived from their existing data. Perhaps the most compelling argument of all is that, in
the end, most of the research is funded by public money, so to make the data freely available, at
least after publication, maximizes the value of the funds provided.
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Outstanding Questions
 What (novel) information can still be
obtained from the roughly two-thirds of
unidentiﬁed fragmentation spectra that
are typically acquired in a proteomics
experiment?
 Linked to the previous question:
can we develop sensitive as well as
speciﬁc identiﬁcation algorithms for
proteomics data that no longer need
to rely on very narrowly deﬁned candi-
date analytes, as, for instance,
obtained from a protein sequence
database?
 Canwe extract information from the
combined (human) proteome data in
public data repositories to guide us to
the most promising tissue types and
sample protocols to obtain more com-
plete coverage of the (human)
proteome?
 How can we make the most of the
combined public omics data from dif-
ferent ﬁelds and what, if any, additional
infrastructure needs to be put in place
to allow these data to become disco-
verable and to allow these data to be
easily connected?
 How can we accelerate the as-yet
very limited use of proteomics data as
a means of enhancing current genome
annotation efforts?
 What privacy and ethics issues will
proteomics data raise in the future and
what can the ﬁeld do to adequately
prepare for these?
 How can we increase the use of
spectral libraries generated from public
proteomics data in existing analysis
workﬂows?
 How can the lingering notion that
reuse of public data in the life sciences
is equivalent to theft or parasitism be
overturned?
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